LGND - Company ID 0000886163
The table below shows LIGAND PHARMACEUTICALS INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $268.09M | $167.13M | $131.31M | $196.25M | $241.54M | $163.56M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $81.18M | $21.43M | $24.54M | $36.08M | $32.10M | $40.50M |
| SG&A |
LIGAND PHARMACEUTICALS INC reported annual revenue of $268.09M for fiscal year 2025. That is up 60.4% from $167.13M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $108.97M (FY 2016) to $268.09M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $92.45M |
| $78.65M |
| $52.79M |
| $70.06M |
| $46.79M |
| $60.01M |
| Operating income | $41.00M | -$22.61M | $11.94M | $3.04M | $103.85M | $37.50M |
| Income tax | $34.51M | $6.55M | $9.84M | $41.23M | -$4.15M | -$5.31M |
| Net income | $124.45M | -$4.03M | $52.15M | -$33.36M | $57.14M | -$2.98M |
| EPS (diluted) | $6.13 | -$0.22 | $2.94 | -$1.98 | $3.31 | -$0.18 |